Background. At present, no uniform definition of human immunodeficiency virus (HIV)-associated lipoatrophy exists. The risk factors for fat atrophy (FA) and central fat deposition (FD) are multifactorial. We assessed the evolution and predictors of FA and FD in HIV-infected men and women.
portant metabolic abnormalities that may occur with body-shape changes. At present, no accepted clinical definition of HIV-associated lipodystrophy exists. Most studies of HIV infection have defined regional fat gain or loss subjectively by patient self-report and/or confirmation on examination . Some studies have used objective tools in their definitions or as covariates, including anthropometry [3, 5, 8, 15, 16, 22] or imaging findings [3, 5, 8, 11, 15, 16] . Many studies have only evaluated recipients of HAART [6, 8, 9, 12, 15, 18] or protease inhibitors (PIs) [23] .
The literature suggests that the syndrome is multifactorial and is associated with host factors, severity of infection, and treatment. It is difficult to disentangle treatment factors [2, 3, 13, 16, 18, 20, 21, 24, 25] from disease severity.
We used population norms [26, 27] and popula-tion studies [28] to develop objective, quantitative anthropometric criteria for HIV-associated fat atrophy and fat deposition and applied them to a large, diverse cohort of HIV-infected adults to determine the prevalence of and risk factors for newly developing fat atrophy and fat deposition over 1 year. The evolution of body shape was also explored.
METHODS

Population. Nutrition for Healthy
Living is a longitudinal study of HIV-infected adults [29] seen semiannually to evaluate nutrition and HIV status. Personnel are recertified semiannually in anthropometry. Participants seen between November 1998 and April 2003 for whom waist and hip circumferences were determined twice over a 10-14-month period were analyzed. The institutional review boards at Tufts-New England Medical Center (Boston, MA) and Miriam Hospital (Providence, RI) approved this study, and informed consent was obtained from participants. Interview data. As described previously [29] , demographic characteristics and data on diet, HIV-related events, and therapy were collected. The following variables were analyzed: poverty (defined as living below 1998 federal poverty level [yes/no]) within the previous 30 days, and diarrhea and loss of appetite within the previous 30 days (yes/no). Testosterone was used by 47 subjects, and 82 used marijuana. Analysis was not performed on use of dronabinaol (7 subjects), prednisone (4 subjects), human growth hormone (4 subjects), and megestrol acetate (6 subjects) because of the small numbers of subjects. Three-day food records were used to collect information on dietary intake.
Laboratory studies. CD4 + cell count, log 10 HIV load, fasting triglyceride level, albumin level, and alanine aminotransferase level were obtained. The nadir CD4 + cell count was determined by self-reported or measured CD4 + cell count, which were highly correlated ( ). The HIV RNA level was R p 0.87 determined using the Roche Amplicor Monitor (Roche Molecular Systems); the lower detection limit was 400 copies/mL.
Physical examinations. Participants were weighed (in kg) on a digital scale without shoes or heavy clothing after a у5-h fast. Height was measured (in cm) by stadiometer, and patients did not wear shoes during measurements.
Body circumferences and skin-fold measurements were taken while subjects were not wearing outer clothing [30] . The average of 3 measures within 3 mm was used. Extreme values identified by intraclass correlation coefficients were deleted if incorrect. Fat-free mass (in kg) was calculated by bioelectric impedance (BIA-101A; RJL Systems) [29, 31, 32] , and resting energy expenditure was calculated by indirect calorimetry [29] . Resting energy expenditure was then divided by fat-free mass (kcal/day/kg).
Anthropometrics were categorized into tertiles by sex. Body fat levels were defined as follows: low, !12% for men and !22% for women; medium, 12%-20% for men and 22%-28% for women; and high, 120% for men and 128% for women.
Definitions of body-shape abnormalities. Fat atrophy, fat deposition, and mixed fat atrophy and fat deposition (hereafter, "mixed FAD") were defined as follows: fat atrophy, triceps skinfold value less than the 10th percentile for age and sex (men, !6 mm; women, !14 mm), based on the National Health and Nutrition Examination Survey (NHANES) values [33] ; fat deposition, waist-to-hip ratio of 10.95 for men and 10.85 for women [27] ; mixed FAD, triceps skin-fold value less than the 10th percentile on the NHANES and waist-to-hip ratio of 10.95 for men and 10.85 for women.
The percentage of persons with fat deposition who had a high waist circumference was determined. A high waist circumference was defined as a value greater than the 80th percentile for waist circumference (based on NHANES III values for those with a body mass index [BMI] of !28; 196.4 cm for men and 186.5 cm for women) [26] .
Analysis. Baseline prevalences of fat atrophy, fat deposition, and mixed FAD were determined. One-year cumulative incidences of newly developed fat atrophy, fat deposition, and mixed FAD were determined among subjects who did not have that particular syndrome at baseline. The percentage of subjects with each syndrome at baseline who no longer had it after 1 year and the percentage of those who continued to have the syndrome over 1 year were calculated. Four hundred forty-five participants were observed for fat atrophy studies, and 452 were observed for fat deposition studies, because 7 subjects had no triceps skin-fold measurement at the end of follow-up.
For each syndrome, independent determinants of baseline prevalence and 1-year cumulative incidence were determined from 3 categories: host factors (demographic characteristics, body composition, and metabolism), HIV disease severity, and HIV therapy. Determinants of incident fat atrophy and fat deposition were first determined among subjects without either syndrome at baseline and next among those without the syndrome of interest at baseline. Generalized estimating equations with a log link (Poisson distribution) [34] were used to obtain 95% CIs using robust standard errors on SAS software, version 9.0 (SAS Institute). Linearity between each determinant and each outcome was checked using restricted cubic splines [35] . When not linear, the determinant was categorized. Significant determinants at on bivariate analysis were entered into P ! .20 multivariate models using forward selection, keeping predictors at and confounders in the final model. Each model P р .05 was adjusted for duration of follow-up in months (range, 10-14 months). Prevalence ratios (PRs) and relative risks (RRs) are reported.
For each syndrome, changes in anthropometrics over the course of 1 year were calculated and compared between incident cases and subjects who remained without the syndrome at 1 year and between those who no longer had the syndrome after 1 year versus those who still had the syndrome. The Wilcoxon rank sum test was used for these comparisons.
RESULTS
Baseline Findings
Baseline characteristics of subjects are shown in table 1, and baseline prevalences of fat atrophy, fat deposition, and mixed FAD are shown in table 2. Among the 117 men and 37 women with fat atrophy, 10% and 32% had a BMI !20, respectively. Twenty-three percent of men with fat deposition and 35% women with fat deposition had a BMI of у30.
Incidence and Evolution of Body-Shape Changes over a 1-Year Period
The evolutions of fat atrophy and fat deposition over a 1-year period are shown in figures 1 and 2, respectively. More men than women had newly developed fat atrophy ( ), and P p .020 more women than men had newly developed fat deposition ( ). Among those who developed fat atrophy, 11% had P p .013 a BMI of !20, and among those who developed fat deposition, 21% had a BMI of 130. At baseline, among 33 men and 12 women who developed mixed FAD syndrome, 55% and 42% had fat atrophy, respectively, and 30% and 33% had fat deposition, respectively. Among 44 men and 19 women with mixed FAD syndrome at baseline, 12 men (27%) and 7 women (37%) no longer had it after 1 year.
Determinants of Prevalence
In multivariate analysis, the baseline prevalence of fat atrophy (data not shown) was 55% lower for subjects in the highest tertile of subscapular skin-fold value, compared with those in the middle and lowest tertiles (PR, 0.45; 95% CI, 0.27-0.75; ). The prevalence was greater among those with higher P p .002 albumin levels (88% of all participants had normal levels) (PR, 1.5 per g/dL; 95% CI, 1.1-2.1;
) and longer continuous P p .018 use of stavudine (Zerit; Bristol-Meyers Squibb) until baseline (PR, 1.009 per month of use; 95% CI, 1.002-1.017;
). P p .018 There was interaction between BMI and race ( ). P p .005 Higher BMI was more protective of fat atrophy among white subjects (PR, 0.08 per 1-unit increase in BMI; 95% CI, 0.01-0.55; ) than among nonwhite subjects (PR, 0.86 per P p .011 1-unit increase in BMI; 95% CI, 0.79-0.93;
). (This P ! .001 model was adjusted for confounding due to changes in BMI since diagnosis of HIV infection.)
In multivariate analysis, prevalence of fat deposition was higher among subjects with a high percentage of body fat (PR, 2.0; 95% CI, 1.2-3.3;
), and it was 2 times higher P p .005 among those in the middle tertile of BMI than among those in the lowest tertile of BMI (PR, 2.0 per tertile; 95% CI, 1.6-2.5;
) and 3.9 times higher among those in the highest P ! .001 tertile of BMI than among those in the lowest tertile of BMI. The prevalence of fat deposition increased with increasing age (PR, 1.03 per year; 95% CI, 1.02-1.05;
) and was higher P ! .001 among white subjects (PR, 1.4; 95% CI, 1.1-1.8;
). P p .004 The prevalence decreased as hip circumference increased: it was 35% lower among subjects in the middle tertile of hip circumference, compared with those in the lowest tertile (PR, 0.65 per tertile; 95% CI, 0.52-0.83; ), and it was 57% lower P ! .001 among those in the highest versus those in the lowest tertile. Higher intake of insoluble fiber was associated with a lower prevalence of fat deposition (PR, 0.96 per g; 95% CI, 0.94-0.99;
). (This model was adjusted for confounding due P p .011 to baseline triceps skin-fold value.)
Determinants of Incidence
Fat atrophy. In multivariate analysis (table 3) , among subjects without fat atrophy or fat deposition at baseline, the risk of new development of fat atrophy was lower among those with larger triceps and larger hips. The risk was greater in subjects who had a higher nadir viral load, who received abacavir, who received stavudine, and who used HAART for a longer time. CD4 + cell count, peak viral load, triglyceride level, albumin level, other types and durations of therapy, testosterone use, marijuana use, race, sex, injection drug use, transmission category, education level, and poverty were not independent predictors.
In a separate model (data not shown) in which subjects with fat deposition at baseline were included, there was increased risk of new development of fat atrophy for white subjects, subjects with higher baseline alanine aminotransferase levels (64% of all participants had normal levels), abacavir use throughout the follow-up period, and any use of nucleoside reverse-transcriptase inhibitors (NRTI) at baseline. There was decreased risk among subjects who had a larger waist, had a higher baseline BMI, engaged in greater physical activity, and used efavirenz throughout the follow-up period.
Fat deposition. In multivariate analysis (table 3) , the risk of newly developing fat deposition among those without fat atrophy or fat deposition at baseline was higher among female subjects, those with a greater percentage of body fat, and those with higher triglyceride levels. It was lower among those with a high school education. Viral load, CD4 + cell count, testosterone level, marijuana use, age, race, injection drug use, lack of stable housing, and dietary fiber intake were not significant independent predictors. In a separate model (data not shown) in which subjects with fat atrophy at baseline were included, the risk of fat deposition was increased with age, greater increases in the CD4 + cell count during follow-up, receipt of nonnucleoside reverse-transcriptase inhibitor-based HAART at baseline, and weight gain during follow-up. The risk decreased with increasing duration of saquinavir use during follow-up. Among men only, subjects in ) than did those P p .003 who maintained their fat deposition. These participants did not differ with regard to changes in skin-fold values or weight.
Comparison of Subjects with a High Waist-to-hip Ratio and/or a Large Waist
There were 217 participants at baseline without a high waistto-hip ratio or high waist circumference. Among those who developed either of these conditions over the course of 1 year, 17 of 51 developed both, 30 of 51 developed only a high waistto-hip ratio, and 4 of 51 developed only a high waist circumference ( ). P ! .001 Compared with subjects who did not develop a high waist circumference, participants who developed a high waist circumference had significantly greater increases in waist-to-hip ratio (+0.04 vs. +0.01; ), waist circumference (+8.0 vs. P ! .001 +0.5 cm;
), hip circumference (+3.8 vs. Ϫ0.3 cm; P ! .001 P ! ), weight (+4.8 vs. Ϫ0.5 kg;
), subscapular skin-.001 P ! .001 fold value (+5.3 vs. Ϫ1.3 mm; ), triceps skin-fold value P ! .001 (+1.3 vs. Ϫ0.8;
), and suprailiac skin-fold value (+3.7 P ! .001 vs. Ϫ1.0;
). P ! .001
DISCUSSION
In contrast with previous reports, our study used objective measurements based on population norms to determine prevalence, cumulative incidence, loss of syndrome, and risk factors for fat atrophy and fat deposition over a 1-year period in a diverse cohort of HIV-infected men and women receiving different treatments in a real-world setting. We believe that our definitions are clinically valid, because participants who developed fat atrophy had subcutaneous fat loss at all skin-fold sites measured. They also lost more abdominal and hip girth, compared with subjects who did not develop fat atrophy. Those who developed fat deposition did not have marked changes in subcutaneous fat (as determined by skin-folds), but they did have changes in body circumferences.
Fat atrophy and fat deposition were common in our cohort, and we believe that they are distinct syndromes. First, the proportion of participants with mixed FAD syndrome actually equaled the probability of having 2 independent syndromes. Moreover, in our cohort, risk factors for fat atrophy differed from those for fat deposition, as in the literature. Development of fat atrophy was more likely to occur in participants with less fat at baseline (i.e., those with low triceps skin-fold measurements and smaller hips), increased disease severity (those with a higher nadir viral load), and stavudine and abacavir use. Continuous HAART use may indicate a longer duration or greater severity of HIV disease. The risk of incident fat deposition was higher in subjects with more body fat at baseline, including for those with more subcutaneous body fat, for women, for those with a high school education, and for those with a higher triglyceride level.
In this study, the prevalences of fat atrophy (35%) and fat deposition (44%) were in the upper range of those reported in the literature. Other studies reported that 15%-36% of patients had fat atrophy [1, 3, 5, 6, 8, 9, 12-16, 19, 21, 24] and 4%-33% of patients had fat deposition [1, 5, 6, 8, 9, 12-16, 19, 20, 24] . Only 1 study of PI recipients reported higher estimated prevalences [6] . Other studies did not separate fat atrophy from fat deposition.
Few studies of the incidence of lipodystrophy have examined fat atrophy and fat deposition separately. The 1-year incidences of fat atrophy (22%) and fat deposition (23%) in our study were in the middle of the range of estimates from 4 incidence studies [2, 4, 7, 20] . Our estimates may differ because we studied an ethnically diverse group of men and women who were or were not receiving different antiretroviral therapies and who may have been healthier and more overweight than were the subjects in other reports and because we used objective, anthropometric definitions of each syndrome.
Few studies have used quantitative measurements to define body-shape changes in HIV-infected patients [3, 5, 16, 22, 36] or as covariates [5] . Most investigators used patients' self-reported findings and/or findings from physical examinations 37] . Our inexpensive, quantitative definitions [26] could be used clinically. Triceps skin-fold values in less than the 10th percentile of the NHANES values were used to define fat atrophy. Subcutaneous fat atrophy is characterized by a loss of extremity fat on dual-energy X-ray absorptiometry (DXA) [38] ; however, DXA cannot distinguish visceral trunk fat from subcutaneous trunk fat. Subcutaneous fat atrophy can also be quantified by CT [15] . Triceps skin-fold values correlated highly with extremity fat noted on CT scans [15] . In our cohort, triceps skin-fold values had a correlation of 0.77 ( ) with P ! .001 extremity fat noted by DXA, and skin-fold values were correlated at all sites (range, 0.42-0.84), suggesting that our def- .005
Disease severity: nadir viral load (log 10 copies/mL) 1. inition does indeed detect generalized subcutaneous fat atrophy. Waist-to-hip ratio has been used in HIV-associated lipodystrophy studies [15] , and both waist-to-hip ratio and waist circumference are significant predictors of cardiovascular disease and other outcomes [27] . HIV-associated visceral fat deposition is characterized by increased intra-abdominal fat noted on CT scans. Abdominal circumference correlates well with intraabdominal fat deposition [15] and may be more specific than waist-to-hip ratio, which may also reflect loss of hip fat, gain in waist circumference, or both. However, in our cohort, subjects who developed high waist-to-hip ratios did not have a decrease in buttock fat, as estimated by hip size. High waistto-hip ratios may indicate less-severe central fat deposition than does waist circumference alone. In our data, only 4 of 51 people developed high waist circumferences alone, whereas 17 of 51 developed both high waist circumference and high waist-tohip ratio, and 30 of 51 developed a high waist-to-hip ratio alone. Patients who developed high waist circumferences had increases in skin-fold values at all sites, whereas those who developed high waist-to-hip ratios did not. High waist circumferences may indicate obesity better than does a high waist-tohip ratio.
We determined host-, virus-, and treatment-related risk factors for body-shape changes: large triceps, an indication of fat stores, was protective against development of fat atrophy. Both disease severity (i.e., high nadir viral load) and treatment were predictive of increased risk of fat atrophy. We also observed a strong association between NRTI use-particularly stavudine use-(i.e., its impact on mtDNA) and fat atrophy. Abacavir use was associated with development of fat atrophy, which has not been previously reported, and may reflect an impact on mtDNA. Lifetime duration of HAART use may indicate a longer period of HIV infection and/or increased severity of disease. In other studies, heterosexual transmission of virus, increased age, male sex, white race, non-injection drug use-related transmission, lower CD4 + cell count, lower BMI, AIDS, longer duration of therapy, use of stavudine, use of any NRTI, and hepatitis C predicted development of fat atrophy [2, 4, 7, 20] .
Among subjects without either fat atrophy or fat deposition at baseline, the risk factors for new development of fat deposition differed from those that predicted new fat atrophy, except for triceps skin-fold value, which predicted both. Host factors that predicted development of fat deposition (sex, education level, higher body fat level, and higher triglyceride level) may reflect poor dietary quality. In a case-control study involving our cohort, lower dietary fiber intake was associated with development of fat deposition [22] . Martinez et al. [7] showed that greater increases in the CD4 + cell count predicted development of any type of lipodystrophy. Others have found that female sex increased risk and injection drug use decreased risk [2] . We carefully chose measurements of fat atrophy and fat deposition based on population standards and studies. One study found that skin-fold measurements had lower reliability than did waist measurements, especially among overweight/obese people [39] . To obtain good reliability, an experienced nutritionist recertified all interviewers semiannually. We averaged 3 measurements within 3 mm for each skin-fold measurement, and the intraclass correlations were 0.99. Thus, with standardized training, anthropometrics could be used clinically. Because overweight or obese people were at lower risk of developing fat atrophy and had higher triceps skin-fold values, it is unlikely that they were misclassified as having fat atrophy. A limitation of the study was the lack of collection of thigh and neck measurements.
Our data suggest that fat atrophy and fat deposition are 2 unique syndromes that occur more frequently as independent syndromes than together. This agrees with the Fat Redistribution and Metabolic Change in HIV Infection study, which suggests that fat atrophy is unique to HIV infection but that fat deposition occurs with equal or greater frequency in HIVuninfected persons [40] . Important avenues of future study include adherence to antiretroviral treatment and body-shape changes, as well as the consequences of body-shape changes.
Fat atrophy and fat deposition are not static processes, and an individual does not develop either syndrome at the time of antiretroviral therapy initiation and simply maintain it. In our study, both syndromes evolved over a 1-year period, as in the HIV Outpatient Study [4] . Body-shape changes-and, potentially, their metabolic and clinical outcomes-are dynamic processes deserving additional longitudinal study.
